PE20091342A1 - Inmunoglobulinas - Google Patents
InmunoglobulinasInfo
- Publication number
- PE20091342A1 PE20091342A1 PE2008001726A PE2008001726A PE20091342A1 PE 20091342 A1 PE20091342 A1 PE 20091342A1 PE 2008001726 A PE2008001726 A PE 2008001726A PE 2008001726 A PE2008001726 A PE 2008001726A PE 20091342 A1 PE20091342 A1 PE 20091342A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- fab
- isolated
- domain according
- immunoglobulins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UN ANTICUERPO HUMANIZADO O QUIMERICO DE REGION CONSTANTE IgG1 QUE SE UNE A ANTIGENOS QUE SE UNE A IL-23 HUMANA, QUE COMPRENDE: i) UN DOMINIO VH SEGUN SEC ID Nº:16, SEC ID Nº: 48, SEC ID Nº: 50, SEC ID. Nº:52, ENTRE OTROS; ii) UN DOMINIO VL SEGUN SEC ID. Nº: 18, SEC ID Nº: 20, SEC ID Nº:22, SEC ID Nº 24, ENTRE OTROS; iii) CDRH3 DE LA SEC ID Nº 3, SEC ID Nº 4, SEC ID Nº 73, ENTRE OTROS. iv) UN Fab, Fab', F(ab'), Fv, DIACUERPO, TRIACUERPO, TETRACUERPO, MINIANTICUERPO, MINICUERPO, VH AISLADA, VL AISLADA O UN dAb. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TAL COMO ARTRITIS REUMATOIDE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97784107P | 2007-10-05 | 2007-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091342A1 true PE20091342A1 (es) | 2009-09-16 |
Family
ID=40378889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001726A PE20091342A1 (es) | 2007-10-05 | 2008-10-03 | Inmunoglobulinas |
Country Status (16)
Country | Link |
---|---|
US (2) | US20090123479A1 (es) |
EP (1) | EP2205637A1 (es) |
JP (1) | JP2011501738A (es) |
KR (1) | KR20100097654A (es) |
CN (1) | CN101889026A (es) |
AR (1) | AR068723A1 (es) |
AU (1) | AU2008306850A1 (es) |
BR (1) | BRPI0818620A2 (es) |
CA (1) | CA2700758A1 (es) |
CL (1) | CL2008002952A1 (es) |
EA (1) | EA201000424A1 (es) |
MX (1) | MX2010003574A (es) |
PE (1) | PE20091342A1 (es) |
TW (1) | TW200930729A (es) |
WO (1) | WO2009043933A1 (es) |
ZA (1) | ZA201002275B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0807710B1 (pt) * | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
SG178804A1 (en) * | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
EP3670538A1 (en) | 2008-04-25 | 2020-06-24 | Dyax Corp. | Antibodies against fcrn and use thereof |
JP5931442B2 (ja) | 2008-08-27 | 2016-06-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 操作された抗IL−23p19抗体の凍結乾燥製剤 |
CA2757237A1 (en) * | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
EP2480251A1 (en) | 2009-09-21 | 2012-08-01 | Peptinov SAS | Carrier conjugates of il-23-peptides and their induced antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
JP6126532B2 (ja) | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗il−23抗体 |
CA2837527C (en) * | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
MX368653B (es) | 2012-05-03 | 2019-10-10 | Boehringer Ingelheim Int | Anticuerpos anti-il-23p19. |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
AU2013364043B2 (en) | 2012-12-21 | 2018-01-04 | Seagen Inc. | Anti-NTB-A antibodies and related compositions and methods |
NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
AU2014238148A1 (en) | 2013-03-15 | 2015-10-08 | Amgen Inc. | Methods for treating psoriasis using an anti-IL-23 antibody |
CA2949405C (en) | 2014-05-22 | 2023-08-01 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
BR112018005175A2 (pt) | 2015-09-17 | 2018-10-16 | Amgen Inc | predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 |
RU2018119732A (ru) | 2015-10-30 | 2019-12-03 | Аблинкс Нв | Полипептиды против il-23 |
JP7391510B2 (ja) | 2015-12-09 | 2023-12-05 | コーバス・ファーマシューティカルズ・インコーポレイテッド | ヒト化抗cd73抗体 |
MX2018007589A (es) | 2015-12-22 | 2018-11-09 | Amgen Inc | Ccl20 como indicador de respuesta clinica a antagonistas de il23. |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
US20210277105A1 (en) | 2018-07-13 | 2021-09-09 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
CN114746120A (zh) | 2019-10-03 | 2022-07-12 | Atyr 医药公司 | 包含抗nrp2抗体的组合物和方法 |
JP2023509373A (ja) | 2019-12-20 | 2023-03-08 | ノヴァロック バイオセラピューティクス, リミテッド | 抗インターロイキン-23 p19抗体およびそれの使用方法 |
CN113698480B (zh) * | 2021-09-18 | 2022-07-01 | 东大生物技术(苏州)有限公司 | 一组il-23单克隆抗体及其医药用途 |
CA3234409A1 (en) * | 2021-10-27 | 2023-05-04 | Luke G. BURMAN | Compositions and methods comprising anti-nrp2a antibodies |
CN114920830B (zh) * | 2022-05-07 | 2023-05-16 | 北京大学 | Vκ4-1-IgLC多肽及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004219625B9 (en) * | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
EP3501537A1 (en) * | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
WO2007024846A2 (en) * | 2005-08-25 | 2007-03-01 | Eli Lilly And Company | Anit-il-23 antibiodies |
EP2354160A1 (en) * | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
-
2008
- 2008-10-02 AR ARP080104318A patent/AR068723A1/es not_active Application Discontinuation
- 2008-10-03 CL CL2008002952A patent/CL2008002952A1/es unknown
- 2008-10-03 TW TW097138322A patent/TW200930729A/zh unknown
- 2008-10-03 WO PCT/EP2008/063289 patent/WO2009043933A1/en active Application Filing
- 2008-10-03 KR KR1020107010032A patent/KR20100097654A/ko not_active Application Discontinuation
- 2008-10-03 CA CA2700758A patent/CA2700758A1/en not_active Abandoned
- 2008-10-03 MX MX2010003574A patent/MX2010003574A/es not_active Application Discontinuation
- 2008-10-03 AU AU2008306850A patent/AU2008306850A1/en not_active Abandoned
- 2008-10-03 JP JP2010527465A patent/JP2011501738A/ja active Pending
- 2008-10-03 US US12/245,426 patent/US20090123479A1/en not_active Abandoned
- 2008-10-03 BR BRPI0818620A patent/BRPI0818620A2/pt not_active IP Right Cessation
- 2008-10-03 CN CN2008801191723A patent/CN101889026A/zh active Pending
- 2008-10-03 EP EP08836275A patent/EP2205637A1/en not_active Withdrawn
- 2008-10-03 US US12/681,413 patent/US20110206686A1/en not_active Abandoned
- 2008-10-03 EA EA201000424A patent/EA201000424A1/ru unknown
- 2008-10-03 PE PE2008001726A patent/PE20091342A1/es not_active Application Discontinuation
-
2010
- 2010-03-30 ZA ZA2010/02275A patent/ZA201002275B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008306850A1 (en) | 2009-04-09 |
US20110206686A1 (en) | 2011-08-25 |
AR068723A1 (es) | 2009-12-02 |
EP2205637A1 (en) | 2010-07-14 |
KR20100097654A (ko) | 2010-09-03 |
WO2009043933A1 (en) | 2009-04-09 |
BRPI0818620A2 (pt) | 2019-09-24 |
ZA201002275B (en) | 2011-06-29 |
MX2010003574A (es) | 2010-04-22 |
JP2011501738A (ja) | 2011-01-13 |
CA2700758A1 (en) | 2009-04-09 |
CN101889026A (zh) | 2010-11-17 |
US20090123479A1 (en) | 2009-05-14 |
TW200930729A (en) | 2009-07-16 |
CL2008002952A1 (es) | 2009-10-16 |
EA201000424A1 (ru) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091342A1 (es) | Inmunoglobulinas | |
IL276695A (en) | Antibodies, pharmaceuticals and their uses | |
TR201901929T4 (tr) | TGFBeta'ya antikorlar. | |
PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
PE20121689A1 (es) | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos | |
PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
UA116874C2 (uk) | Імунокон'югат анти-мезотеліну | |
PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
MX2011008843A (es) | Anticuerpos humanizados que se unen a cd19 y sus usos. | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
PE20060418A1 (es) | Anticuerpos antagonistas de il-17 | |
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
PE20060287A1 (es) | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM | |
WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
PE20191328A1 (es) | Conjugados de farmacos y anticuerpos anti-ccr7 | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
PE20090368A1 (es) | Anticuerpos anti-igf | |
IL290591B1 (en) | Antibody drug preparations (ADC) that bind to 191P4D12 proteins | |
RU2016100892A (ru) | Антитела против tweakr и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |